Mirna Therapeutics (SYBX) and Its Competitors Financial Analysis
Mirna Therapeutics (NASDAQ: SYBX) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Mirna Therapeutics to similar companies based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, earnings, dividends and risk.
Risk & Volatility
Mirna Therapeutics has a beta of 3.59, suggesting that its share price is 259% more volatile than the S&P 500. Comparatively, Mirna Therapeutics’ rivals have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.
This table compares Mirna Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mirna Therapeutics Competitors||-13,073.01%||230.26%||-22.81%|
This is a breakdown of current ratings and price targets for Mirna Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mirna Therapeutics Competitors||190||909||1681||67||2.57|
Mirna Therapeutics currently has a consensus price target of $13.13, suggesting a potential downside of 31.82%. As a group, “Biopharmaceuticals” companies have a potential upside of 2.75%. Given Mirna Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Mirna Therapeutics has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 18.6% of Mirna Therapeutics shares are held by insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Mirna Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mirna Therapeutics Competitors||$578.59 million||$241.91 million||-6.43|
Mirna Therapeutics’ rivals have higher revenue and earnings than Mirna Therapeutics. Mirna Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Mirna Therapeutics rivals beat Mirna Therapeutics on 8 of the 11 factors compared.
Mirna Therapeutics Company Profile
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.